{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:55:59Z","timestamp":1792119359858,"version":"4.4.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA160216"],"award-info":[{"award-number":["CA160216"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA210849"],"award-info":[{"award-number":["CA210849"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50CA127003"],"award-info":[{"award-number":["P50CA127003"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ajpath.2024.11.005","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T18:56:34Z","timestamp":1734634594000},"page":"437-452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Cholangiocarcinoma Targeted Therapies"],"prefix":"10.1016","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4915-9640","authenticated-orcid":false,"given":"Haley","family":"Ellis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Braconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeel","family":"Bardeesy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2024.11.005_bib1","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","article-title":"Pathogenesis, diagnosis, and management of cholangiocarcinoma","volume":"145","author":"Rizvi","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2024.11.005_bib2","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ajpath.2024.11.005_bib3","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.11.005_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ajpath.2024.11.005_bib5","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ajpath.2024.11.005_bib6","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2024.11.005_bib7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2024.11.005_bib8","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.11.005_bib10","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41416-022-01908-1","article-title":"Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing","volume":"127","author":"Neumann","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajpath.2024.11.005_bib11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41586-022-05066-5","article-title":"Truncated FGFR2 is a clinically actionable oncogene in multiple cancers","volume":"608","author":"Zingg","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2024.11.005_bib12","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/2159-8290.CD-20-1669","article-title":"FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma","volume":"11","author":"Cleary","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.11.005_bib13","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1200\/GO.20.00030","article-title":"Lack of targetable FGFR2 fusions in endemic fluke-associated cholangiocarcinoma","volume":"6","author":"Kongpetch","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib14","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2024.11.005_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00080","article-title":"Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype","volume":"2","author":"Jain","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib16","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib17","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2024.11.005_bib19","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2217\/fon-2020-0429","article-title":"FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements","volume":"16","author":"Bekaii-Saab","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib20","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","article-title":"Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial","volume":"30","author":"Rodon","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpath.2024.11.005_bib21","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.11.005_bib22","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.11.005_bib24","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/1078-0432.CCR-23-1317","article-title":"Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-altered cholangiocarcinoma","volume":"30","author":"Wu","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2024.11.005_bib25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jhep.2023.10.041","article-title":"Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma","volume":"80","author":"DiPeri","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib26","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a004002","article-title":"Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy","volume":"5","author":"Krook","year":"2019","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"10.1016\/j.ajpath.2024.11.005_bib27","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","article-title":"Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma","volume":"19","author":"Krook","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ajpath.2024.11.005_bib28","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/2159-8290.CD-21-1168","article-title":"EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion-positive cholangiocarcinoma","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.11.005_bib29","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","article-title":"RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations","volume":"13","author":"Subbiah","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.11.005_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4009","article-title":"Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors","volume":"41","author":"Borad","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib31","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.3019","article-title":"Preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors: a phase Ib\/II clinical trial","volume":"41","author":"Piha-Paul","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib32","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.434","article-title":"Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: results from phase II clinical trial","volume":"42","author":"Javle","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib33","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jamaoncol.2024.3900","article-title":"Rogaratinib plus atezolizumab in cisplatin-ineligible patients with FGFR RNA-overexpressing urothelial cancer: the FORT-2 phase 1b nonrandomized clinical trial","volume":"10","author":"Sweis","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib34","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/hep.32424","article-title":"Biology of IDH mutant cholangiocarcinoma","volume":"75","author":"Wu","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.ajpath.2024.11.005_bib35","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/s41591-018-0095-6","article-title":"Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate","volume":"24","author":"Bunse","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpath.2024.11.005_bib36","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.ajpath.2024.11.005_bib37","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1172\/JCI90644","article-title":"Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas","volume":"127","author":"Kohanbash","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2024.11.005_bib38","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1101\/gad.294991.116","article-title":"Mutant IDH1 regulates the tumor-associated immune system in gliomas","volume":"31","author":"Amankulor","year":"2017","journal-title":"Genes Dev"},{"key":"10.1016\/j.ajpath.2024.11.005_bib39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13073-020-00787-6","article-title":"Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types","volume":"12","author":"Bao","year":"2020","journal-title":"Genome Med"},{"key":"10.1016\/j.ajpath.2024.11.005_bib40","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/2159-8290.CD-21-1077","article-title":"Mutant IDH inhibits IFNgamma-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.11.005_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/science.adl6173","article-title":"Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity","volume":"385","author":"Wu","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2024.11.005_bib42","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s43018-021-00201-z","article-title":"Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas","volume":"2","author":"Friedrich","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ajpath.2024.11.005_bib43","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/2159-8290.CD-15-1442","article-title":"Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma","volume":"6","author":"Saha","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.11.005_bib44","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1126\/science.1236062","article-title":"Mellinghoff IK: An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells","volume":"340","author":"Rohle","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2024.11.005_bib45","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","article-title":"Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers","volume":"9","author":"Popovici-Muller","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.ajpath.2024.11.005_bib46","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2024.11.005_bib47","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.2217\/fon-2020-1274","article-title":"Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma","volume":"17","author":"Aguado-Fraile","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib48","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.11.005_bib49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41698-022-00304-5","article-title":"Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma","volume":"6","author":"Cleary","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib50","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a020768","article-title":"The EGFR family: not so prototypical receptor tyrosine kinases","volume":"6","author":"Lemmon","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib51","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ajpath.2024.11.005_bib52","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajpath.2024.11.005_bib53","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib54","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2024.11.005_bib55","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1200\/JCO.23.02010","article-title":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial","volume":"42","author":"Ohba","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib56","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4097","article-title":"Circulating tumor DNA (ctDNA) analyses in patients with HER2-positive biliary tract cancer (BTC) treated with trastuzumab deruxtecan (T-DXd): exploratory results from the HERB trial","volume":"41","author":"Ohba","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib57","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","article-title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study","volume":"24","author":"Strickler","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib58","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib59","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib60","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.3390\/cancers14163996","article-title":"Overcoming resistance to HER2-directed therapies in breast cancer","volume":"14","author":"Schlam","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ajpath.2024.11.005_bib61","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.jhep.2022.01.012","article-title":"Collaborators: Receptor tyrosine kinase co-amplification and benefit from HER2 inhibitors in biliary tract cancers","volume":"76","author":"Casolino","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib62","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib63","first-page":"e69","article-title":"Treatment and survival outcome of BRAF-mutated metastatic colorectal cancer: a retrospective matched case-control study","volume":"17","author":"Kayhanian","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ajpath.2024.11.005_bib64","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1158\/1078-0432.CCR-23-1926","article-title":"Comparative genomic analysis and clinical outcomes of BRAF-mutated advanced biliary tract cancers","volume":"29","author":"Tang","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2024.11.005_bib65","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1476","article-title":"Association of BRAF variants with disease characteristics, prognosis, and targeted therapy response in intrahepatic cholangiocarcinoma","volume":"6","author":"Xin","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ajpath.2024.11.005_bib66","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib67","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ejca.2012.11.019","article-title":"Resistance to BRAF-targeted therapy in melanoma","volume":"49","author":"Sullivan","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajpath.2024.11.005_bib68","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2024.11.005_bib69","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-13-3122","article-title":"BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact","volume":"20","author":"Rizos","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2024.11.005_bib70","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2024.11.005_bib71","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-genomic and immune evolution of melanoma acquiring MAPKi resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ajpath.2024.11.005_bib72","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/j.molcel.2024.06.027","article-title":"Functional and structural insights into RAS effector proteins","volume":"84","author":"Mozzarelli","year":"2024","journal-title":"Mol Cell"},{"key":"10.1016\/j.ajpath.2024.11.005_bib73","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamasurg.2021.5679","article-title":"Association of KRAS variant subtypes with survival and recurrence in patients with surgically treated intrahepatic cholangiocarcinoma","volume":"157","author":"Zhou","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ajpath.2024.11.005_bib74","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-023-01839-y","article-title":"Adagrasib: first approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ajpath.2024.11.005_bib75","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.11.005_bib76","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1158\/1078-0432.CCR-18-0368","article-title":"KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition","volume":"25","author":"Misale","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2024.11.005_bib77","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRAS G12C mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib78","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS inhibitor disables oncogenic signalling and tumour growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2024.11.005_bib79","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","article-title":"Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer","volume":"13","author":"Kemp","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.11.005_bib80","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical acquired resistance to KRAS(G12C) inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.11.005_bib81","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRAS(G12C) inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2024.11.005_bib82","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/23808993.2021.1910023","article-title":"Rizzo A: Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives","volume":"6","year":"2021","journal-title":"Expert Rev Precision Med Drug Dev"},{"key":"10.1016\/j.ajpath.2024.11.005_bib83","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1158\/2159-8290.CD-15-0443","article-title":"An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101","volume":"5","author":"Doebele","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.11.005_bib84","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"trial investigators: Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib85","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.ajpath.2024.11.005_bib86","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.3104","article-title":"Mechanisms of acquired resistance to TRK inhibitors","volume":"40","author":"Harada","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib87","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.11.005_bib88","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nrclinonc.2017.188","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib89","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.19.02551","article-title":"State-of-the-art strategies for targeting RET-dependent cancers","volume":"38","author":"Subbiah","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib90","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib91","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib92","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2024.11.005_bib93","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx089","article-title":"ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer","volume":"109","author":"Pietrantonio","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ajpath.2024.11.005_bib94","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib95","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/annonc\/mdy090","article-title":"RET fusions in a small subset of advanced colorectal cancers at risk of being neglected","volume":"29","author":"Pietrantonio","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib96","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7555\/JBR.27.20130030","article-title":"The MDM2-p53 pathway revisited","volume":"27","author":"Nag","year":"2013","journal-title":"J Biomed Res"},{"key":"10.1016\/j.ajpath.2024.11.005_bib97","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026336","article-title":"The role of MDM2 amplification and overexpression in tumorigenesis","volume":"6","author":"Oliner","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.ajpath.2024.11.005_bib98","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.543","article-title":"Efficacy and safety of the MDM2\u2013p53 antagonist BI 907828 in patients with advanced biliary tract cancer: data from two phase Ia\/Ib dose-escalation\/expansion trials","volume":"41","author":"Yamamoto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib99","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/PAS.0000000000001006","article-title":"MDM2 amplification in intrahepatic cholangiocarcinomas: its relationship with large-duct type morphology and uncommon KRAS mutations","volume":"42","author":"Kim","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib100","doi-asserted-by":"crossref","first-page":"634","DOI":"10.21873\/cdp.10153","article-title":"Efficacy and safety of external-beam radiation therapy for unresectable primary or local recurrent cholangiocarcinoma","volume":"2","author":"Murakami","year":"2022","journal-title":"Cancer Diagn Progn"},{"key":"10.1016\/j.ajpath.2024.11.005_bib101","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.3390\/jcm12113638","article-title":"MDM2 implications for potential molecular pathogenic therapies of soft-tissue tumors","volume":"12","author":"Sun","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ajpath.2024.11.005_bib102","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In\u00a0vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2024.11.005_bib103","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0092-8674(03)00308-8","article-title":"Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads","volume":"113","author":"Cordenonsi","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.ajpath.2024.11.005_bib104","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS4179","article-title":"A phase IIa\/IIb, open-label trial of BI 907828, an MDM2\u2013p53 antagonist, in patients with locally advanced\/metastatic biliary tract carcinoma or pancreatic ductal adenocarcinoma: Brightline-2","volume":"41","author":"Goyal","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib105","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1158\/1078-0432.CCR-14-2506","article-title":"Elucidation of acquired resistance to Bcl-2 and MDM2 inhibitors in acute leukemia in\u00a0vitro and in\u00a0vivo","volume":"21","author":"Hoffman-Luca","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2024.11.005_bib106","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ajpath.2024.11.005_bib107","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2020.12.010","article-title":"MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage","volume":"39","author":"Kalev","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2024.11.005_bib108","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1158\/1535-7163.MCT-05-0103","article-title":"Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers","volume":"4","author":"Karikari","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ajpath.2024.11.005_bib109","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4102","article-title":"Genomic profile of intrahepatic cholangiocarcinoma with MTAP loss","volume":"40","author":"Tang","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajpath.2024.11.005_bib110","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1021\/acs.jmedchem.1c01900","article-title":"Fragment-based discovery of MRTX1719, a synthetic lethal inhibitor of the PRMT5\u2217MTA complex for the treatment of MTAP-deleted cancers","volume":"65","author":"Smith","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.ajpath.2024.11.005_bib111","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ajpath.2024.11.005_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105492","article-title":"Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition","volume":"300","author":"Bedard","year":"2024","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2024.11.005_bib113","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1182\/bloodadvances.2023010554","article-title":"Resistance to PRMT5-targeted therapy in mantle cell lymphoma","volume":"8","author":"Long","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.ajpath.2024.11.005_bib114","article-title":"Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets","author":"Vijay","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.ajpath.2024.11.005_bib115","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/nm.3968","article-title":"SWI\/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2","volume":"21","author":"Kim","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpath.2024.11.005_bib116","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1158\/0008-5472.CAN-24-0398","article-title":"Comprehensive target engagement by the EZH2 inhibitor tulmimetostat allows for targeting of ARID1A mutant cancers","volume":"84","author":"Keller","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajpath.2024.11.005_bib117","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpath.2024.11.005_bib118","article-title":"Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma","volume":"4","author":"Pandey","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ajpath.2024.11.005_bib119","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944024004462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944024004462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T01:09:19Z","timestamp":1772327359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944024004462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":119,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0002944024004462"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2024.11.005","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cholangiocarcinoma Targeted Therapies","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2024.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}